This Ivy League Dropout Can Predict How You Might Die

The Dealroom with Shamus Madan

Kian Sadeghi shares his journey, beginning with a personal tragedy that inspired the creation of Nucleus. He explains the decreasing cost and increasing value of genome sequencing and his decision to drop out of UPenn to focus on build a biotech company. Kian shares the challenges he faced and the strategies he used to raise $18 Million from investors such as Alexis Ohanian. He highlights the advantages of being a young founder and demystifies genome sequencing. The conversation explores the future of genome data, its integration with personal hardware, and the hurdles in building consumer trust. Kian also reflects on the role of PhDs, the long-term vision for Nucleus, the lessons learned from failures, and how he manages stress.

🐦 Follow the host: https://x.com/shamusmadan

📩 Join The Dealroom: https://dealroompodcast.com/subscribe

Learn More About Nucleus Genomics: https://mynucleus.com/

Huge shout out to Savraj Singh for making this episode possible!

(0:00) Kian Sadeghi's personal tragedy and the inspiration behind Nucleus (2:54) The decreasing cost and value of genome sequencing (6:10) Learning about human biology and the decision to drop out (10:49) Overcoming challenges and raising funds for Nucleus (14:57) Advantages of being a young founder and explaining genome sequencing (19:19) The future of genome data and integration with personal hardware (23:13) Building Nucleus: Challenges, consumer trust, and prioritizing tasks (31:12) The role of PhDs and the long-term vision for Nucleus (33:29) Learning from failures, current fears, and handling stress (36:09) Best and worst advice and reflections for the younger self